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Background: In the PREDICT study, a randomised controlled trial comparing dexamethasone with prednisolone
in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), almost a quarter of patients
deteriorated soon after starting treatment. The primary objective of this post-hoc analysis was to test the hypothesis
that a focal demyelination pattern is associated with early deterioration after corticosteroid treatment and to explore
whether various clinical characteristics are associated with deterioration after corticosteroid treatment.
Methods: Clinical outcome was categorised into early deterioration and non-early deterioration. A neurophysiologist
blinded for treatment outcome scored electrophysiological data into following categories: pure focal versus non-focal
distribution of demyelination and no/minor versus moderate/severe sensory involvement. Additionally, we compared
electrophysiological and clinical baseline parameters, with emphasis on previously reported possible associations.
Results: Early deterioration was found in 7 out of 33 patients (21%). Ten patients had pure focal distribution of
demyelination, of whom 5 had early deterioration; 23 patients had non-focal distribution, of whom 2 had early
deterioration (p = 0.02). Higher mean median nerve sensory nerve conduction velocity (SNCV) was found in patients
with early deterioration compared to patients with non-early deterioration (52.6 and respectively 40.8 m/s, p = 0.02).
Conclusion: Pure focal distribution of demyelination and lesser sensory electrophysiological abnormalities may be
associated with early deterioration in CIDP patients treated with corticosteroids.
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Corticosteroids and intravenous immunoglobulin (IVIg)
are both efficacious treatments for chronic inflammatory
demyelinating polyradiculoneuropathy (CIDP). However,
first choice of treatment is often based on physicians’
preference, due to absence of difference in treatment
efficacy [1,2]. Predicting factors of treatment response in
CIDP would greatly ease the choice of first treatment. Thus
far, reliable clinical and electrophysiological predictors of
treatment response are limited.
Earlier, we performed the PREDICT trial in which
remission rates were compared between pulsed dexa-
methasone treatment and daily prednisolone in typical
CIDP patients with diffuse sensory and motor involvement
[3]. Forty percent of the whole group achieved a remission,
defined as a sustained improvement one year after start* Correspondence: f.eftimov@amc.uva.nl
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Amsterdam, 1100 Amsterdam, DD, The Netherlands
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reproduction in any medium, provided the orof treatment, without a significant difference between both
treatments. Strikingly, almost a quarter of the participants
deteriorated soon after start of trial treatment.
Early deterioration after corticosteroids is a well-recog-
nised and enigmatic phenomenon reported in patients
with multifocal motor neuropathy (MMN) [4]. To a lesser
extent, deterioration after corticosteroids has also been
reported in pure motor CIDP and Lewis-Sumner syn-
drome (LSS) [5,6]. The hallmark of MMN is the presence
of conduction blocks (CBs) caused by focal demyelination,
while signs of diffuse demyelination such as reduced
motor nerve conduction velocities (MNCVs) are less
frequently found [7]. This is in contrast with typical
motor and sensory CIDP in which both diffuse and
focal features can occur. Some studies have suggested
that in pure motor CIDP and LSS conduction blocks
are relatively more frequent than other demyelinating
features, when compared to typical CIDP [6,8]. These
findings prompted us to consider an association betweenl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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CBs with focal demyelination pattern in acquired demye-
linating neuropathies, including typical CIDP.
A few small retrospective studies have reported an
association between extent of axonal damage or extent
of sensory involvement and treatment response after
corticosteroids, but none have focussed on early deteri-
oration [9-11]. In this post-hoc analysis we studied pos-
sible associations with deterioration after corticosteroid
treatment, focussing on the pattern of demyelination
and previously reported clinical and electrophysiological




The PREDICT trial included treatment naïve patients
who had been diagnosed as having definite or probable
CIDP according to the ENMC diagnostic criteria [12].
All patients had a typical CIDP with clinically symmet-
rical sensory and motor involvement. Patients with a
pure motor CIDP or LSS were excluded from the trial.
Participants were randomly assigned to receive either six
monthly courses of oral pulsed dexamethasone (40 mg
daily during four consecutive days) or 8 months daily
prednisolone with a tapering schedule [3]. All partici-
pants gave written informed consent for the original trial
including analysis of baseline characteristics. The trial
protocol was approved by the ethics committees of all
participating centres.
Treatment outcome
In the PREDICT trial remission was the primary out-
come defined as improvement of at least three points on
the Rivermead Mobility Index (RMI) and improvement
of at least one point on the Inflammatory Neuropathy
Cause and Treatment (INCAT) disability scale as com-
pared with baseline or when the best possible score of a
scale had been reached. For this post-hoc analysis we
dichotomised outcome into early deterioration and non-
early deterioration. Early deterioration was defined as
any decrease on the RMI and/or increase on the INCAT
disability scale at first scheduled trial follow-up visit at 8
weeks or at a prior unscheduled visit if such occurred.
The group of non-early deterioration group encompassed
all other patients.
Baseline characteristics
Electrophysiological baseline parameters were re-assessed
and scored into categories by a neurophysiologist blinded
for treatment and treatment outcome. The EFNS/PNS
criteria for CIDP were used to define a conduction block
and number of segments with a MNCV within the demye-
linating range (<70% of lower limit of normal) [2]. Nervesegments over pressure points (elbow and fibula) and
nerves with distal compound muscle action potential
(CMAP) peak-peak amplitude below 1 mV were excluded
from analysis [2]. The number of CBs was defined as the
sum of definite and probable CBs and was expressed as
number per patient and as number per measured nerve
segments with distal CMAP amplitude above 1 mV.
The mean MNCV in arms and legs was calculated using
exclusively nerve segments without CB. The distal CMAP
amplitude and sensory nerve action potential (SNAP)
amplitude of the median nerve were expressed as means.
If both median nerves were tested in a patient, the mean
of these values was used for group comparison. In non-
recordable median nerves the CMAP and SNAP was
scored as 0.
Categorization of pure focal versus non-focal pattern
of demyelination was based on the assumption that CB
is a sign of focal demyelination while reduced MNCV in
a nerve segment without CB is a sign of diffuse demye-
lination. We defined a pure focal demyelination pattern
as the presence of two or more definite or probable CBs
without the presence of MNCVs within the demyelinating
range in other nerve segments. All other patients were
considered having a non-focal demyelinating pattern.
Electrophysiological sensory involvement at baseline was
categorised into no/minor versus moderate/severe. Moder-
ate/severe sensory involvement was defined as the presence
of SNAP amplitude below the lower limits of normal
(LLN) in at least two arm nerves. If a single arm nerve
was tested, moderate/severe sensory involvement was
scored if this single SNAP amplitude was below the
LNN. All other patients were scored as having minor
sensory involvement. Sensory nerve conduction velocity
(SNCV) of the median nerve was calculated if distal and
proximal SNAP recordings were available.
Clinical baseline characteristics included Medical Research
Council (MRC) sum score of 12 predefined muscle groups
(maximum of 60), grip strength expressed as mean grip
strength from both hands measured with a Vigorimeter,
INCAT sensory sum score (range 0-20), RMI (range 0-15)
and INCAT disability (range 0-10) scores at baseline.
Statistical analysis
Differences between baseline characteristics were tested
for significance using chi-square test and, if needed, a
Fisher exact test for nominal data, Student’s t-test for
interval data with normal distribution and Mann-Whitney
test for all other data (expressed as median values), using a
p value of .05 as threshold for statistical significance.
Results
Forty patients participated in the PREDICT trial. Seven
patients had an alternative diagnosis during follow-up
and were excluded from analysis. Alternative diagnoses
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lymphoma, IgM paraproteinemia and transthyretine asso-
ciated hereditary amyloidosis. Details on these patients
have been published elsewhere [13].
From 33 CIDP patients seven (21%) deteriorated within
8 weeks after start of treatment (Figure 1), four patients
had dexamethasone and three had prednisolone. In three
of these patients deterioration occurred within two weeks.
Clinical characteristics of patients with early deterioration
can be found in Table 1. One patient (Table 1, patient 7)
had an asymmetric distribution of weakness based on
MRC scores and grip strength. All other 32 patients had
symmetrical distribution of weakness. In all included
patients weakness was present in both arms and legs. Legs
were predominantly affected in six patients (all without
deterioration), arms were predominantly affected in two
(one deteriorated, Table 1, patient 2).
From the seven patients who deteriorated, five patients
had ultimately a favorable outcome (Table 1). Three pa-
tients responded to IVIg, one patient failed to improve
on IVIg but improved after switch to prednisolone, one
patient (prednisolone) had only a temporary deterioration,
continued prednisolone treatment which later resulted
in a remission. Two patients did not respond to any
treatment, including various immunosuppressive agents.
Of the 26 remaining patients, four patients (all prednisol-
one) deteriorated during or after tapering of prednisolone
(10 to 33 weeks after start of treatment, Figure 1).
All patients fulfilled the electrophysiological EFNS/PNS
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Figure 1 Outcome of patients during PREDICT study.motor nerve segments per patient was 7 (IQR 4-12, with a
median of 6 segments with a CMAP peak-peak amplitude
above 1 mV). Pure focal distribution pattern of demye-
lination was found in 10 patients. Of these patients, CB
was the only demyelinating feature in seven patients
while three patients had also abnormal F-responses in
nerves without a conduction block and/or prolonged
distal latencies.
The median number of examined sensory arm nerves
per patient was 3 (IQR 2-4). In three patients only one
sensory arm was tested. Two patients had normal
sensory conduction studies, based on a limited num-
ber of tested nerves. Both patients had clinically sen-
sory involvement with INCAT sensory sum scores of
2 and 11 and both deteriorated (patient 4 and 6 in
Table 1). All other patients had electrophysiological
sensory abnormalities.
Five out of seven (71%) patients with early deterior-
ation had a focal distribution pattern of demyelination,
compared to five out of 26 (19%) patients without early
deterioration (p = 0.02, Table 2). Total number of conduc-
tion blocks per examined nerve segment, median CMAP
amplitude of the median nerve and mean MNCV did not
differ between both groups.
Mean SNCV in median nerve was higher in patients
with early deterioration compared to other patients (52.6
and 40.8 m/s respectively, p = 0.02). There was no differ-
ence in the predefined categories of sensory involvement
and the median SNAP amplitude of the median nerve
between both groups.arly deterioration 
(7 patients, 21%) 
Late deterioration 
(4 patients, 12%) 
ment    
) 
Deterioration 
(11 patients, 33%) 
Alternative diagnosis 
(7 patients) 




Change at endpoint compared to baseline Response
to other
treatments
MRC GS INCAT-SS ΔINCAT-DS ΔRMI ΔMRC ΔGS Δ INCAT-SS
1/D 48 51 np 5 1 -4 -2 -15 npa P
2/D 53 108 5 6 1 0 5 -52 -3 No
3/D 47 18 3 1 3 -7 -5 -5 1 IVIg
4/D 52 125 2 1 4 -10 -7 -25 0 IVIg
5/P 48 47 7 8 4 -7 -6 -27 -2 IVIg
6/P 50 9 11 2 3 -2 np np np P
7/P 51 83 9 4 2 0 1 -47 5 No
Legend: Abbreviations: D dexamethasone, P prednisolone, np not performed, MRC Medical Research Council Sum Score (maximum of 60), MGS Mean Grip Strength
(mean of both arms, Vigorimeter) INCAT-DS, Inflammatory Neuropathy Cause and Treatment Disability Scale (maximum score of 10, higher scores represent more
disability), RMI Rivermead Mobility Index (maximum score of 15, higher scores represent less disability), INCAT-SS Inflammatory Neuropathy Cause and Treatment
Sensory Sum Score (maximum score of 20, higher scores represent more sensory deficit). aINCAT-SS in this patient at time of deterioration was 10.
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In this post-hoc analysis we found that pure focal demye-
lination and higher mean SNCV of the median nerve were
associated with early clinical deterioration in patients
with CIDP after starting corticosteroid treatment. No
association was found with other electrophysiologal and
clinical baseline parameters.
Deterioration in patients with CIDP might be due to
progression of disease and/or insufficient therapeutic
effect of corticosteroids. Most patients in the PREDICT
trial who deteriorated however, worsened dramaticallyTable 2 Distribution of baseline characteristics according to t
Early deterioration (7
Baseline electrophysiological parameters
Pattern of demyelination, number (%)
Pure focal 5 (71%)
Non-Focal 2 (29%)
CMAP amplitude median nerve (median, mV) 10 (6)
MNCV arms (mean, m/s) 49.7 (10)
MNCV legs (mean, m/s) 39.6 (3)
Number of CB per examined segments (mean) 0.31 (0.2)
Sensory involvement severity, number (%)
Normal/minor 4 (57%)
Moderate/severe 3 (43%)
SNAP amplitude median nerve (median, μV) 15 (13)
SNCV median nerve (mean m/s) 52.6 (7)
Baseline clinical parameters
MRC sum scores (mean) 49.9(2)
Grip strength (median, kPa) 102 (180)
INCAT sensory sum score (median) 6(7)
INCAT disability score (median) 3(2)
Rivermead Mobility Index (median) 12(3)
Legend: Abbreviations: MNCV motor nerve conduction velocity, CB conduction block
inflammatory neuropathy cause and treatment. Numbers in brackets represent thewithin weeks after start of treatment. Furthermore, all
PREDICT-patients were treated with pulses of dexametha-
sone or were receiving high doses of daily prednisolone
at the time of deterioration. In a recent trial comparing
IVIg with intravenous methylprednisolone in CIDP a
comparable percentage of patients (24%) deteriorated after
start of pulses intravenous methylprednisolone [14].
Earlier studies have suggested that higher MNCV, higher
SNCV and higher SNAP amplitudes are associated with
poor corticosteroid response [9-11]. In our study we fo-
cussed on early deterioration instead of poor responsereatment outcome
















(definite and probable summated), MRC Medical Research Council, INCAT
standard deviation for mean values or interquartile range for median values.
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found higher mean SNCV in patients who deteriorated.
These findings suggest that an electrophysiological profile
with predominantly motor involvement with focal demye-
lination might be a risk factor for deterioration after
corticosteroid treatment. Moreover, our data further
suggests that it might be difficult to identify patients
likely to deteriorate based on clinical characteristics as
all patients had a typical clinical picture of CIDP with dif-
fuse symmetric sensory and motor involvement, although
discrepancy between clinical findings of evident motor
involvement and only minor sensory involvement was
found in two patients who deteriorated (Table 1).
Except for myasthenia gravis we are not aware of any
other immune-mediated diseases in which corticosteroids
are known to have such a detrimental effect. This prompted
us to consider corticosteroid-induced changes in nerve
conduction rather than disease progression due to lack
of immunological response to corticosteroids. Threshold
techniques have shown that conduction in inflammatory
neuropathies can fail if membrane potential hyperpolarizes
too far from threshold. In general, motor nerves are more
vulnerable than sensory nerves that are able to counteract
hyperpolarization. Critically conducting motor nerves,
as can be seen in nerves with conduction blocks, might
be especially vulnerable for changes in rest membrane
potential [15,16]. This vulnerability of motor nerves might
explain why in most of our patients increase in disability
was accompanied by deterioration on MRC sum score
and/or grip strength rather than increase of sensory deficit
(Table 1). A possible mechanism of this detrimental effect
of corticosteroids might be axonal hyperpolarization by
up-regulation of Na+K+ pump activity. Up-regulation of
hyperpolarizing Na+K+ pumps have been recently shown
in muscle fibres from muscle biopsies from healthy volun-
teers treated with a course of dexamethasone [17]. Studies
on effect of corticosteroids on nerve conduction and
membrane potentials have not been published.
Unfortunately, the number of patients in this study is too
small to provide solid evidence on associations between
baseline characteristics and treatment outcome. The main
limitation of the study is possible bias associated with a
post-hoc analysis. This bias was somewhat limited as
patients were assessed during prescheduled follow-up
visits and predefined measurements and treatment out-
come. Another important limitation of this study is the
lack of standardised electroneurography protocols which
led to testing of different nerves segments and variable
numbers of examined nerve segments. Furthermore, most
electroneurography protocols focussed on examination of
motor nerves as abnormalities in these nerves are needed
to meet the electrophysiological criteria for CIDP. This
has resulted in limited number of examined sensory nerves
in some participants. To overcome some of these limita-tions we made categories of distribution of demyelination
and sensory involvement which were assessed by a neuro-
physiologist blinded for treatment outcome. Considering
the explorative nature of this study, categories were based
on the presence of conduction blocks indicating focal
demyelination and low MNCV indicating diffuse demye-
lination in a nerve segment. We chose not to use abnor-
mal or absent F-waves or prolonged distal motor nerve
latencies for this category distinction as one could argue
whether these are focal or non-focal features. To explore
possible bias we also performed an analysis in which
focal demyelination was defined as CB without any other
demyelinating features. This analysis led to similar results
(data not shown).
Finally, we performed analyses including all PREDICT
participants and deterioration throughout the whole trial
period to explore possible bias due to exclusion of patients
with alternative diagnosis or our definition of cut-off time
point for early deterioration. Significant association with
deterioration was still present with focal demyelination
pattern, but not for SNCV.
Larger studies are needed to confirm the association
of focal pattern of demyelination and early deterioration.
Extensive electroneurography protocols might be useful, not
only to confirm diagnosis, but also to explore the predictive
value of electrophysiological phenotypes for treatment re-
sponse. Identifying patients who deteriorate after treatment
is important as IVIg can be administered as alternative
treatment. We did not find a difference in number of CBs
between both groups but CBs might be more frequent in re-
sponders to IVIg compared to non-responders [18]. When
combining these results, in patients with clinically typical
CIDP and a pure focal demyelination pattern IVIg might be
the preferred treatment rather than corticosteroids. Alterna-
tively, in CIDP patients with a non-focal pattern of demye-
lination, corticosteroids can safely be administered, which
has advances over IVIg as there is increasing evidence that
long-term remission can be achieved after a relatively short
period of treatment with corticosteroids [13,14].
Conclusions
Focal pattern of demyelination and lesser sensory electro-
physiological abnormalities may be associated with deteri-
oration after corticosteroid treatment in typical CIDP.
Further studies are needed to confirm these associations
and to explore the predictive value of different electro-
physiological phenotypes for treatment response.
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